Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 14/20 | 0.64 |
| ▸ | ULK2 | Q8IYT8 | 5/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | BCL6 | P41182 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496523 | 0.89 | STK17B (0.54) | ULK1ULK2BRD4BCL6FLT3 | |
| SCHEMBL3495051 | 0.88 | BCL6 (0.63) | ULK1ULK2PTK2BRD4BCL6 | |
| SCHEMBL3496651 | 0.87 | BCL6 (0.52) | ULK1ULK2BRD4BCL6PRKCQ | |
| SCHEMBL3496821 | 0.87 | ULK1 (0.66) | ULK1ULK2BRD4KITFLT3 | |
| SCHEMBL3496433 | 0.85 | ULK1 (0.49) | ULK1ULK2 | |
| SCHEMBL3494060 | 0.85 | PRKCQ (0.57) | ULK1ULK2PTK2BRD4BCL6 | |
| SCHEMBL3494581 | 0.84 | BRD4 (0.53) | ULK1ULK2BRD4KITFLT3 | |
| SCHEMBL3496354 | 0.84 | BCL6 (0.49) | ULK1ULK2BRD4BCL6FLT3 | |
| SCHEMBL3495182 | 0.84 | ULK1 (0.56) | ULK1ULK2PTK2BRD4KIT | |
| SCHEMBL3495452 | 0.83 | ULK1 (0.49) | ULK1ULK2KITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | ULK1 832/4885ULK2 407/4885PTK2 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.